• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Michael Fitzhugh

Articles by Michael Fitzhugh

FDA adcom votes down nebulized cipro developed by Aradigm, Grifols

Jan. 16, 2018
By Michael Fitzhugh
FDA advisors considering Linhaliq, an experimental Aradigm Corp. drug for a rare but severe respiratory disease in patients with chronic lung infections, declined to support a new drug application for it, citing inconsistent efficacy data and concern over the endpoint of pivotal trials.
Read More

Evolus seeks $75M to bring back aesthetic market entry

Jan. 11, 2018
By Michael Fitzhugh
SAN FRANCISCO – Little more than five minutes' drive from Botox-maker Allergan plc's chief research center in Irvine, Calif., Evolus Inc. is prepping for a $75 million IPO that, if successful, could create new competition for the botulinum toxin king.
Read More

CFDA seeking greater efficiency, quality, says its chief scientist

Jan. 11, 2018
By Michael Fitzhugh
SAN FRANCISCO – Exuberance over China's ascendant biopharma sector formed a near-deafening roar at the 6th Annual Wuxi Global Forum Tuesday, where Ruyi He, chief scientist of the CFDA's Center for Drug Evaluation (CDE), spoke to the accelerating pace of the Republic's regulatory reform.
Read More

Celgene launches $7B bid for Impact Biomedicines

Jan. 9, 2018
By Michael Fitzhugh
SAN FRANCISCO – The 36th Annual J.P. Morgan Healthcare Conference started off with a bang Monday, as Celgene Corp. talked up a proposed $7 billion acquisition of San Diego-based Impact Biomedicines Inc. built around Impact’s lead candidate, the phase III JAK2 inhibitor fedratinib, a potential treatment for myelofibrosis, a rare disease of the bone marrow.
Read More

Gossamer takes wing with $100M series A round

Jan. 8, 2018
By Michael Fitzhugh
Gossamer Bio Inc., a new company looking to leverage what it called "an asset-rich in-licensing environment," has raised $100 million from Arch Venture Partners and Omega Funds to rev up operations, advance trials for its early and late-stage candidates, and further augment its pipeline.
Read More

RNA play: Stoke lands $40M series A to advance therapies for severe genetic disease

Jan. 5, 2018
By Michael Fitzhugh
Stoke Therapeutics Inc., a new company developing antisense oligonucleotide therapies for severe genetic diseases, raised a $40 million series A financing from Apple Tree Partners, its sole investor.
Read More

Expansion Therapeutics draws $55.3M to back RNA therapies

Jan. 4, 2018
By Michael Fitzhugh
Expansion Therapeutics Inc. has raised a $55.3 million series A round to advance its portfolio of RNA-targeted small-molecule medicines to treat rare diseases.
Read More

New Year's IPOs seek warm reception

Jan. 3, 2018
By Michael Fitzhugh
Just days before one of biotech's busiest weeks, a quartet of IPO filings by Menlo Therapeutics Inc., Restorbio Inc., Armo Biosciences Inc. and Solid Biosciences LLC are outlining the case for investing millions of dollars in the development of new therapies.
Read More

Atara gets FDA go-ahead for EBV cell therapy

Jan. 2, 2018
By Michael Fitzhugh
An off-the-shelf T-cell therapy for people with rituximab-refractory Epstein-Barr virus (EBV) flagged by the FDA for both orphan and breakthrough status is headed into dual phase III trials after the agency green-lighted its developer, Atara Biotherapeutics Inc., to make the move. Earlier data on the candidate, tabelecleucel, formerly known as ATA-129, suggests it might significantly improve the odds of survival for people who develop lymphomas and other lymphoproliferative disorders caused by EBV after solid organ or blood cell transplants.
Read More

La Jolla gifted early stocking stuffer with FDA shock drug approval

Dec. 27, 2017
By Michael Fitzhugh
Two months ahead of its PDUFA date, La Jolla Pharmaceutical Co. has won FDA approval for a new vasopressor capable of increasing blood pressure in adults with septic or other distributive shock.
Read More
Previous 1 2 … 95 96 97 98 99 100 101 102 103 … 179 180 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe